Carbon Biosciences
Carbon Biosciences: Advancing gene therapy potential with a unique, nature-tested parvovirus platform.
Founded
2021Carbon Biosciences: Advancing gene therapy potential with a unique, nature-tested parvovirus platform.
Carbon Biosciences, founded with a mission to advance the potential of gene therapy, focuses on developing treatments for devastating diseases using a proprietary platform based on novel parvoviruses. These viruses, evolved over millions of years, are engineered to target specific tissues, carry larger genetic cargo, and minimize neutralizing immunity, allowing for potential re-dosing. The company leverages recent clinical and manufacturing advances to extend the reach of genetic medicines.
Notable figures affiliated with Carbon Biosciences include a team of experienced drug developers and scientists. The company has attracted significant investment from leading venture capital firms in the biotech sector. Key achievements include the development of their proprietary CBN vector library, which enhances the precision and efficacy of gene therapies. Carbon Biosciences is making a substantial impact by addressing previously elusive diseases, thereby pushing the boundaries of genetic medicine.
Companies similar to Carbon Biosciences include Rampart Bioscience, Chameleon Biosciences, Strm.Bio and Caribou Biosciences.
Carbon Biosciences was founded in 2021.
Carbon Biosciences' headquarters is located in Lexington, MA, US.
Carbon Biosciences' most recent funding round was for $38M (USD) in June 2022.
As of Jun 21, 2022, Carbon Biosciences has disclosed funding of $38M (USD). Undisclosed round amounts are excluded.
Carbon Biosciences has 45 employees as of Feb 5, 2024.
Caribou Biosciences
cariboubio.com
